Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

How Will The Roxadustat Market Valuation Change Between Now And 2029?

The market size of roxadustat has experienced substantial growth in the preceding years. An increase from $6.44 billion in 2024 to $6.86 billion in 2025 is anticipated, at a compound annual growth rate (CAGR) of 6.5%. The expansion witnessed during the historic period is credited to the sanctioning of regulatory approvals in prime markets, positive outcomes from clinical trials, a rising incidence of chronic kidney disease, increased consciousness about the management of anemia, and government backing for treatments of anemia.

In the coming years, the roxadustat market is predicted to witness significant growth, reaching the value of “$8.95 billion by 2029 with a compound annual growth rate (CAGR) of 6.9%. The projected growth for this period is attributed to continuing new indication research, a surge in healthcare spending, the preference for non-injectable anemia treatments, growing favorable reimbursement policies, and an increasing elderly population. Notable trends during the forecast period include shifting towards oral anemia treatments, rising competition from alternative remedies, extending licensing agreements, heightened investment in hypoxia-inducible factor research, and a focus on treatments that prioritize the patient’s needs.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21280&type=smp

Which Growth Drivers Are Shaping The Roxadustat Market Outlook?

The escalating prevalence of people suffering from chronic kidney disease (CKD) is anticipated to fuel the expansion of the Roxadustat market. CKD is a progressive medical condition in which the kidneys lose their effectiveness gradually, often resulting in kidney failure if not addressed timely. The global surge in the numbers of individuals affected by chronic kidney disease can be attributed to aspects like the aging population, amplifying instances of diabetes, hypertension and unhealthy lifestyle habits. Roxadustat plays a crucial role in managing chronic kidney disease by enhancing the secretion of erythropoietin, which escalates the production of red blood cells and tackles anemia that is commonly associated with the disease, resulting in an improvement in kidney functionality and patients’ quality of life. For example, a report issued by the Australian Institute of Health and Welfare (AIHW), a government agency based in Australia, in December 2024, revealed a slight yearly surge in the mortality rates due to chronic kidney disease, registering a growth of 4.2% in 2021 and 6.2% in 2022. Consequently, the increasing prevalence of people with chronic kidney disease (CKD) is propelling the growth of the Roxadustat market.

What Segmentation Insights Are Provided In The Roxadustat Market Research?

The roxadustat market covered in this report is segmented –

1) By Type: 20mg, 50mg

2) By Product Formulation: Oral Tablets

3) By Distribution Channel: Hospitals, Specialty Pharmacies, Dialysis Centers

4) By End-User Application: Chronic Kidney Disease-Associated Anemia, Other Anemia Conditions

Which Notable Trends Are Transforming The Roxadustat Market Outlook?

Major companies operating in the Roxadustat market are opting for reimbursement under the high-tech drugs scheme to ensure broader patient access by reducing financial barriers, thereby accelerating market uptake and demonstrating the cost-effectiveness of their innovative therapies. The high-tech drugs scheme is a government-managed program primarily in Ireland that provides reimbursement for the dispensing of expensive, highly specialized medications typically prescribed in hospital settings. For instance, in September 2022, Astellas Pharma Company Ltd., a US-based pharmaceutical company announced that its EVRENZO (Roxadustat) has been granted reimbursement under the High-Tech Drugs Scheme in Ireland. Roxadustat is the first in a new class of orally administered hypoxia-inducible factor prolyl hydroxylase (HIF PH) inhibitors licensed and reimbursed in Ireland. The results showed Roxadustat was effective in achieving and maintaining target hemoglobin levels (10-12g/dL) in patients with symptomatic anemia of CKD, regardless of dialysis status and prior ESA treatment.

Which Firms Are Driving Innovation Within The Roxadustat Market?

Major companies operating in the roxadustat market are AstraZeneca PLC, Viatris Inc., Astellas Pharma Inc., Dr. Reddy’s Laboratories Ltd., Hetero Drugs Limited, Akebia Therapeutics Inc., Metrochem API Private Limited, FibroGen Inc., AMI Lifesciences, Lee Pharma Ltd., Faran Shimi Pharmaceutical Company, Maithri Drugs Pvt. Ltd., Clearsynth Labs Ltd., Bal Pharma, HEMA Pharmaceuticals Pvt. Ltd., Zhejiang Hengkang Pharmaceutical Co. Ltd., Kimia Biosciences Pvt. Ltd., Lewens Labs Pvt. Ltd., Hangzhou Longshine Bio-Tech Co. Ltd., GLR Innovations, Suzhou Biosyntech Co. Ltd., Shanvr Life Sciences Pvt. Ltd.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/roxadustat-global-market-report

Which Regional Markets Are Emerging As Key Hubs For The Roxadustat Market?

North America was the largest region in the Roxadustat market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the roxadustat market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=21280&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model